AmorChem closes second early-stage biotech fund at $44.2 mln
AmorChem Group has launched AmorChem II Fund LP, a seed-stage biotechnology investor, at an initial capitalization of $44.2 million. The fund secured commitments from the Québec government, Fonds de solidarité FTQ, U.S. pharmaceutical giant Merck and other limited partners. AmorChem, which now manages $86 million, invests in promising life sciences projects originating from Québec universities and research centres that can be built into startups able to attract investors and pharmaceutical partners. The Montréal investor is led by General Partners Elizabeth Douville and Inès Holzbaur. A new general partner, Maxime Ranger, joined with Fund II's launch.
6 December 2017•4 mins read
